pioglitazone has been researched along with cyclosporine in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (10.53) | 29.6817 |
| 2010's | 16 (84.21) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Afshari, CA; Eschenberg, M; Hamadeh, HK; Lee, PH; Lightfoot-Dunn, R; Morgan, RE; Qualls, CW; Ramachandran, B; Trauner, M; van Staden, CJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Barber, J; Dawson, S; Kenna, JG; Paul, N; Stahl, S | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Ambroso, JL; Ayrton, AD; Baines, IA; Bloomer, JC; Chen, L; Clarke, SE; Ellens, HM; Harrell, AW; Lovatt, CA; Reese, MJ; Sakatis, MZ; Taylor, MA; Yang, EY | 1 |
| Cantin, LD; Chen, H; Kenna, JG; Noeske, T; Stahl, S; Walker, CL; Warner, DJ | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Aleo, MD; Bonin, PD; Luo, Y; Potter, DM; Swiss, R; Will, Y | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Norman, BH | 1 |
| Câmara, NO; Campaholle, G; Cenedeze, MA; de Paula Antunes Teixeira, V; dos Reis, MA; Pacheco-Silva, A; Pereira, MG | 1 |
| Chen, Z; Hasegawa, T; Okada, K; Okita, Y; Tanaka, Y | 1 |
| Abd-Elrahman, KS; Abdel-Galil, AG; El-Gowelli, HM; El-Mas, MM; Saad, EI | 1 |
| Abd-Elrahman, KS; Abdel-Galil, AG; Abdel-Rahman, AA; El-Gowelli, HM; El-Mas, MM; Saad, EI | 1 |
| Abd-Elrahman, KS; Abdel-Galil, AG; El-Gowelli, HM; El-Gowilly, SM; El-Mas, MM; Saad, EI | 1 |
| Chai, L; Feng, W; Li, M; Liu, L; Shi, W; Wang, J; Wang, Q; Yan, X; Zhai, C; Zhang, Q; Zhu, Y | 1 |
2 review(s) available for pioglitazone and cyclosporine
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug Induced Liver Injury (DILI). Mechanisms and Medicinal Chemistry Avoidance/Mitigation Strategies.
Topics: Animals; Cell Line; Cell Survival; Chemical and Drug Induced Liver Injury; Drug Discovery; Drug Evaluation, Preclinical; Hepatocytes; Humans; Liver; Mitochondria, Liver; Pharmaceutical Preparations; Risk Assessment; Tissue Distribution | 2020 |
17 other study(ies) available for pioglitazone and cyclosporine
| Article | Year |
|---|---|
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
Interference with bile salt export pump function is a susceptibility factor for human liver injury in drug development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Assay; Biological Transport; Cell Line; Cell Membrane; Chemical and Drug Induced Liver Injury; Cytoplasmic Vesicles; Drug Evaluation, Preclinical; Humans; Liver; Rats; Reproducibility of Results; Spodoptera; Transfection; Xenobiotics | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
In vitro inhibition of the bile salt export pump correlates with risk of cholestatic drug-induced liver injury in humans.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Cholestasis; Drug-Related Side Effects and Adverse Reactions; Humans; Insecta; Rats; Risk Factors | 2012 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds.
Topics: Chemical and Drug Induced Liver Injury; Cytochrome P-450 Enzyme Inhibitors; Cytochrome P-450 Enzyme System; Decision Trees; Drug Evaluation, Preclinical; Drug-Related Side Effects and Adverse Reactions; Glutathione; Humans; Liver; Pharmaceutical Preparations; Protein Binding | 2012 |
Mitigating the inhibition of human bile salt export pump by drugs: opportunities provided by physicochemical property modulation, in silico modeling, and structural modification.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Bile Acids and Salts; Cell Line; Chemical and Drug Induced Liver Injury; Humans; Quantitative Structure-Activity Relationship | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Human drug-induced liver injury severity is highly associated with dual inhibition of liver mitochondrial function and bile salt export pump.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Chemical and Drug Induced Liver Injury; Humans; Male; Mitochondria, Liver; Rats; Rats, Sprague-Dawley; Severity of Illness Index | 2014 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Pioglitazone limits cyclosporine nephrotoxicity in rats.
Topics: Animals; Arterioles; Blood Pressure; Body Weight; Creatinine; Cyclosporine; Drug Interactions; Gene Expression; Hypoglycemic Agents; Immunosuppressive Agents; Kidney; Kidney Diseases; Male; Pioglitazone; Plasminogen Activator Inhibitor 1; Rats; Rats, Wistar; RNA, Messenger; Smad3 Protein; Smad7 Protein; Thiazolidinediones; Transforming Growth Factor beta1 | 2006 |
Renoprotective immunosuppression by pioglitazone with low-dose cyclosporine in rat heart transplantation.
Topics: Animals; Apoptosis; Cardiotonic Agents; Cyclosporine; Dose-Response Relationship, Drug; Drug Therapy, Combination; Gastric Lavage; Graft Rejection; Graft Survival; Heart Transplantation; Immunosuppressive Agents; Injections, Subcutaneous; Interferon-gamma; Interleukin-2; Kidney Diseases; Kidney Function Tests; Male; Peptide Fragments; Pioglitazone; Protective Agents; Random Allocation; Rats; Thiazolidinediones; Transplantation, Heterotopic | 2009 |
Role of PPAR gamma/nitric oxide synthase signaling in the cyclosporine-induced attenuation of endothelium-dependent renovascular vasodilation.
Topics: Anilides; Animals; Arginine; Carbachol; Cyclosporine; Endothelium-Dependent Relaxing Factors; Immunosuppressive Agents; In Vitro Techniques; Kidney; Male; NG-Nitroarginine Methyl Ester; Nitric Oxide Synthase; Phenylephrine; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Signal Transduction; Thiazolidinediones; Vasoconstrictor Agents; Vasodilation | 2010 |
Pioglitazone abrogates cyclosporine-evoked hypertension via rectifying abnormalities in vascular endothelial function.
Topics: Animals; Antioxidants; Aorta; Cyclosporine; Endothelium, Vascular; Hypertension; Hypoglycemic Agents; Immunosuppressive Agents; Lipids; Nitric Oxide Synthase Type III; Pioglitazone; Rats; Thiazolidinediones | 2011 |
PPARγ dependence of cyclosporine-isoprenaline renovascular interaction: roles of nitric oxide synthase and heme oxygenase.
Topics: Animals; Cyclosporine; Drug Interactions; Enzyme Inhibitors; Heme Oxygenase (Decyclizing); Isoproterenol; Kidney; Male; Nitric Oxide Synthase; Pioglitazone; PPAR gamma; Rats; Rats, Wistar; Receptors, Adrenergic, beta; Thiazolidinediones; Vasodilation | 2011 |
S1P induces pulmonary artery smooth muscle cell proliferation by activating calcineurin/NFAT/OPN signaling pathway.
Topics: Animals; Calcineurin; Calcium; Cations, Divalent; Cell Proliferation; Cyclosporine; Estrenes; Female; Gene Expression Regulation; Ion Transport; Lysophospholipids; Myocytes, Smooth Muscle; NFATC Transcription Factors; Osteopontin; Pioglitazone; PPAR gamma; Primary Cell Culture; Pulmonary Artery; Pyrrolidinones; Rats; Rats, Sprague-Dawley; RNA, Small Interfering; Signal Transduction; Sphingosine; Type C Phospholipases | 2019 |